{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4136","value":"14580"},{"groupId":"OG001","spread":"18490","value":"67480"},{"groupId":"OG002","spread":"79270","value":"223700"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"The PK (AUCinf) of AZD8853 in serum when administered in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy 1 Part A.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEAN","populationDescription":"PK analysis set included all participants who received at least one dose of IP with at least one reportable concentration.","reportingStatus":"POSTED","timeFrame":"0 hour, 15 minutes, 2 hours, 6 hours, 24 hours, 168 hours and 336 hours post EOI of Cycle 1 (each cycle equals to 21 days)","title":"Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUCinf) of AZD8853","type":"SECONDARY","unitOfMeasure":"h*ug/mL"}